Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03275870|
Recruitment Status : Completed
First Posted : September 8, 2017
Results First Posted : March 24, 2020
Last Update Posted : April 2, 2020
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body. The cause of the disease is still unknown and common treatments are only sometimes effective. Overactivity of the immune system has been associated with HS and molecules that cause inflammation have been found in the skin from people with HS. Current therapies have long-term risks including antibiotic resistance and the investigators aim to find new safe and effective therapies for HS.
Hydroxychloroquine is a medication that has been used safely in other diseases for many years. The investigators believe that hydroxychloroquine has the potential to improve HS through multiple mechanisms. Patients enrolled in this study will be treated with hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients with HS to look for inflammatory molecules that we could possibly target for the treatment of HS. Blood samples will be taken at baseline and following 6 months of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Hidradenitis Suppurativa Hidradenitis Acne Inversa Boils Follicular Occlusion Triad Follicular Occlusion Tetrad||Drug: Hydroxychloroquine||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa|
|Actual Study Start Date :||September 28, 2017|
|Actual Primary Completion Date :||June 30, 2019|
|Actual Study Completion Date :||June 30, 2019|
Experimental: Hydroxychloroquine treatment
Hydroxychloroquine 200mg BID for 6 months
Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
Other Name: Plaquenil
- Change in Disease Severity [ Time Frame: 6 months ]Comparison of baseline and post-treatment Sartorius severity scoring Sartorius scoring: minimum 0, no maximum, higher scores mean a worse outcome
- Change in Quality of Life [ Time Frame: 6 months ]Comparison of baseline and post-treatment self-reported quality of life Dermatology Life Quality Index score: minimum 0, maximum 30. higher scores mean worse outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03275870
|United States, Pennsylvania|
|University of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Elena M Gonzalez Brant, MD||University of Pittsburgh|